INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc.
The investigation concerns whether Savara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 27, 2025, Savara issued a press release 'announc[ing] that the Company received [a refusal to file] letter from the FDA for the [Biologics License Application] of MOLBREEVI as a therapy to treat patients with autoimmune PAP.'
On this news, Savara's stock price fell $0.90 per share, or 31.69%, to close at $1.94 per share on May 27, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle PeytonPomerantz LLP
[email protected]
646-581-9980 ext. 7980
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Evogene Ltd (EVGN) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ...
This article first appeared on GuruFocus. Total Revenue (H1 2025): $3.2 million, up from $2.3 million in H1 2024. Research and Development Expenses (H1 2025): $4.8 million, down from $6.5 million in H1 2024. Sales and Marketing Expenses (H1 2025): $800,000, down from $1.1 million in H1 2024. Total Operating Expenses (H1 2025): $7.7 million, down from $11.1 million in H1 2024. Cash and Short-term Bank Deposits (End of H1 2025): $11.7 million. Operating Loss (H1 2025): $6.1 million, down from $9.4 million in H1 2024. Net Loss (H1 2025): $7.7 million, down from $9.8 million in H1 2024. Cash Usage (Q2 2025): $2.4 million. Financing Income (H1 2025): $732,000, up from $373,000 in H1 2024. Loss from Operations Held for Sale, Net (H1 2025): $2.2 million, up from $0.8 million in H1 2024. Warning! GuruFocus has detected 6 Warning Signs with EVGN. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Evogene Ltd (NASDAQ:EVGN) reported an increase in total revenues for the first half of 2025 to approximately $3.2 million, up from $2.3 million in the first half of 2024, driven by strong seed sales from its subsidiary Casterra. The company executed a cost reduction plan, resulting in a significant decrease in operating expenses, with total operating expenses net for the first half of 2025 at approximately $7.7 million compared to $11.1 million in the same period last year. Evogene Ltd (NASDAQ:EVGN) completed the sale of Lavie Bio's assets and the MicroBoost AI for Ag tech-engine to ICL, generating significant cash flow and enhancing the company's financial position. The company is focusing on maximizing the value of its ChemPass AI platform, which has been strengthened by the completion of the GeneRator AI foundation model developed in collaboration with Google Cloud. Evogene Ltd (NASDAQ:EVGN) successfully raised $4.4 million through its ATM facility, providing a solid financial foundation and operational runway of approximately 18 months. Negative Points Evogene Ltd (NASDAQ:EVGN) is undergoing a strategic shift, which includes significant organizational changes and workforce reductions, potentially impacting employee morale and operational stability. The company reported a net loss for the first half of 2025 of approximately $7.7 million, although this was a decrease from the $9.8 million loss in the same period last year. There is uncertainty regarding the commercialization of Casterra's castor seed inventory, as the company is exploring options to sell seeds directly or grow and sell grain. The ongoing geopolitical situation in Israel, including the conflict with Hamas and Hezbollah, poses risks and uncertainties that could affect the company's operations and financial performance. Evogene Ltd (NASDAQ:EVGN) faces challenges in achieving peak sales and establishing new partnerships, particularly in the pharma and agriculture sectors, which are crucial for future growth. Q & A Highlights Q: How much castor seed inventory does Evogene have, and what are the plans if the current customer does not place a follow-on order? A: Ofer Haviv, President and CEO, stated that while he won't disclose specific inventory amounts, Evogene has a few hundred tons of Casterra seed ready for sale. The company plans to sell these seeds to partners or use them to grow grain through subcontractors, as they have a better understanding of cultivation in certain territories. Initial results from trials in Brazil and Kenya are promising. Q: What steps need to occur before Evogene can announce a castor oil business? A: Ofer Haviv explained that Evogene is currently focused on grain cultivation and selling grain to partners. There is significant demand from oil factories in Africa and Brazil. The main challenge is the cost of growing castor, which Evogene aims to address with its unique variety and growth protocols. Q: The stock is still low. When will it start going up? A: Ofer Haviv mentioned that while the stock market is unpredictable, Evogene is finalizing a new company presentation and website to reflect its strategy. The company plans to announce new collaborations in pharma and agriculture, which should strengthen its value proposition and potentially impact the stock positively. Q: How representative are operating expenses in Q2 2025, and are all cost reductions fully reflected? A: Ofer Haviv confirmed that the third and fourth quarters are expected to show continued declines in expenses across R&D, marketing, and G&A, reflecting the full impact of cost reductions. Q: What was revenue in Q2 '25, and how should we think about peak sales? A: Ofer Haviv noted that Casterra is currently the only activity producing regular sales, primarily from seed sales. The company is in discussions with multiple partners to expand castor oil activities, focusing on reducing cultivation costs to maximize yield versus expenses. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
James Hardie Industries PLC (JHIUF) Q1 2026 Earnings Call Highlights: Navigating Market ...
This article first appeared on GuruFocus. Total Net Sales: $900 million, a 9% decrease from the previous year. Adjusted EBITDA: $226 million with a margin of 25.1%, a decline of 21% year-over-year. Adjusted Net Income: $127 million. Adjusted Diluted EPS: $0.29 per share. Free Cash Flow: $104 million, an increase of 88%. North America Net Sales: Declined 12%, with a 3% increase in average net sales price. North America Adjusted EBITDA Margin: 32.1%, down 400 basis points year-over-year. APAC Net Sales: Declined 10%, with a 25% decrease in volumes and a 22% rise in ASP in Australian dollars. Europe Net Sales: Increased 7%, with a 2% increase in euros. FY26 Adjusted EBITDA Guidance: $1.05 billion to $1.15 billion. FY26 Adjusted Diluted EPS Guidance: $0.75 to $0.85. Capital Expenditures for FY26: Approximately $400 million. Gross Debt: Approximately $5.1 billion with an annualized effective interest rate of approximately 5.7%. Warning! GuruFocus has detected 13 Warning Signs with APAJF. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points The integration of James Hardie and AZEK has created a leading provider of exterior home and outdoor living solutions, significantly expanding the company's offering and market reach. AZEK's business delivered a strong June quarter, exceeding guidance with mid-single-digit sell-through growth in Deck, Rail & Accessories, demonstrating resilience in a challenging market. James Hardie has secured multi-year national exclusivity agreements with several large homebuilders, enhancing its market position and demonstrating strong partnerships. The company has made meaningful progress on cost synergy realization, achieving over 50% of its run rate target for general and administrative cost savings. James Hardie's innovation strategies, including new product launches and enhancements like ColorPlus, are expected to drive future growth and material conversion opportunities. Negative Points Demand in North America, particularly in single-family new construction, has been weaker than anticipated, leading to a more cautious inventory approach by distributors and dealers. The company has adjusted its expectations for FY26 due to softer demand, with market demand expected to decline by high single digits. James Hardie experienced a 12% decline in North America net sales in the quarter, driven by lower volumes and a challenging market environment. The integration of AZEK has led to a more conservative outlook for Deck, Rail & Accessories, with anticipated low single-digit sell-through growth. Persistent raw material inflation, particularly in pulp, has negatively impacted margins, although this headwind is expected to subside through the year. Q & A Highlights Q: Can you help us parse out the single-family outlook versus the inventory element, as it seems more pronounced than expected? A: Aaron Erter, CEO: Our Q1 results were as expected, embedded in our FY26 guide. Customers ordered to more optimistic expectations earlier in the year, but as the outlook softened, they focused on inventory. Single-family new construction starts from January through March impacted our April through June results. We anticipated this dynamic, hence our updated guidance. Q: Given the tougher demand backdrop, are there any additional cost management strategies you can implement? A: Aaron Erter, CEO: We are leveraging the Hardie Operating System, focusing on yield and managing shifts. We are also integrating two companies, which may present opportunities for cost efficiencies. Our team remains disciplined and focused on accelerating our efforts. Q: How much of the Q1 volume decline was due to inventory destocking, and will this impact persist into Q2? A: Aaron Erter, CEO: In Q1, inventory aside, we performed in line with the market, down mid-single digits. We expect some destocking to continue in Q2 and Q3 as customers adopt a more cautious inventory approach. Q: How did the single-family new construction in the South evolve from April to today, and is it stabilizing? A: Rachel Wilson, CFO: Single-family new construction estimates have shifted significantly since May, with South permits declining sequentially. We are prudently planning for continued softness, impacting our guidance. Q: Can you explain the differences in EBITDA guidance for AZEK compared to previous expectations? A: Rachel Wilson, CFO: There are technical differences, such as including stock-based compensation in our EBITDA. Our guidance reflects a conservative channel inventory positioning and potential macroeconomic impacts, despite strong performance in the AZEK business. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
Macmahon Holdings Ltd (MCHHF) Full Year 2025 Earnings Call Highlights: Record Revenue and ...
This article first appeared on GuruFocus. Revenue: $2.4 billion, a new record. EBIT (A): $171 million, a new record. EBIT (A) Margin: Improved to 7.1% from 6.9% in the prior year. Operating Cash Flow: Up 35% to $407 million. Free Cash Flow: Up 89% to $141 million. Net Debt: Increased by 11% year-on-year but reduced by over 30% from the first half position. Gearing: Dropped to 19% after the acquisition of Decmil. Dividends: Increased by 43% to $0.015 per share, fully franked. ROACE: 20.5%, reaching the long-term target of 20%. Order Book: $5.4 billion as of June 30, up from $4.3 billion at the half year. Revenue Growth: 20% year-on-year. EBIT (A) Growth: 22% year-on-year. Effective Tax Rate: 32.2%. FY26 Revenue Guidance: $2.6 billion to $2.8 billion. FY26 EBIT (A) Guidance: $180 million to $195 million. Warning! GuruFocus has detected 9 Warning Signs with MCHHF. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Macmahon Holdings Ltd (MCHHF) achieved record revenue and EBIT(A) of $2.4 billion and $171 million, respectively, with an improved EBIT(A) margin of 7.1%. The company reported a significant increase in free cash flow, up 89% to $141 million, supporting a robust balance sheet with lower debt levels. Macmahon Holdings Ltd (MCHHF) increased its dividend payout by 43% to $0.015 per share, reflecting a payout ratio of 31% on underlying earnings per share. The order book grew to $5.4 billion, with $2.1 billion of work secured for FY26, indicating strong future revenue potential. The company has a diversified business mix, with underground and civil infrastructure now accounting for 42% of group revenue, reducing capital intensity and improving returns. Negative Points Net debt increased by 11% year-on-year, although it was reduced by over 30% from the first half position. The acquisition of Decmil, while beneficial, contributed to the increase in net debt and required careful integration and management. The effective tax rate was higher at 32.2%, influenced by withholding taxes from Indonesia, which may impact future profitability. The company's reliance on commodity markets, particularly gold and copper, exposes it to potential volatility in commodity prices. Despite strong performance, the company faces competitive pressures in tender pricing, requiring careful management to maintain margins. Q & A Highlights Q: What does the current tender environment mean for pricing, and how is the competitive landscape looking? A: Michael Finnegan, CEO, explained that the pricing environment is sensible, providing both clients and contractors with choices and options. This reduces desperation and promotes longer, more transparent relationships. The company aims to reduce net debt to $100 million, allowing for more selectivity in projects. Q: Is there a need for mergers and acquisitions (M&A) to reach the long-term target of $1 billion from each segment, or can this be achieved organically? A: Michael Finnegan, CEO, stated that the company believes it can achieve this target organically, given the addressable markets. However, they remain open to M&A if it accelerates growth, but there is no current focus on acquisitions. Q: Can you provide an update on current projects and contracts, specifically regarding the Anglo American contract and Greenbushes? A: Michael Finnegan, CEO, noted that the Anglo American contract has come to term, and they are providing smaller services. The company is exploring options for future contracts. At Greenbushes, operations are steady, and they are ready to expand scope if needed. Q: With the increased syndicated debt facility to $550 million, is there a risk of making a poor acquisition decision? A: Michael Finnegan, CEO, assured that the team is focused on execution and will only consider acquisitions that align with strategic goals. The new debt facility provides improved covenants and pricing, offering financial flexibility without immediate plans for large acquisitions. Q: How does the company plan to manage its capital allocation policy moving forward? A: Michael Finnegan, CEO, emphasized balancing dividend payments with financial flexibility to execute strategy. The company aims to maintain debt within guide rails while growing earnings per share and dividends, focusing on strategic growth and disciplined cost management. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
